全身免疫炎症指数（SII）预测骨肉瘤（OSA）患者预后的有效性已被广泛分析，但尚未获得一致的结果。因此，本荟萃分析的重点是确定 SII 对 OSA 的精确预后价值。我们全面检索了 PubMed、Embase、Web of Science、Cochrane Library 和中国知网 (CNKI) 的电子数据库，从建库到 2024 年 2 月 24 日同时，通过计算汇总风险比 (HR) 以及 95% 置信区间 (CI) 来评估 SII 预测 OSA 预后的效率。此外，还根据合并比值比 (OR) 和 95%CI 分析了 SII 与 OSA 临床病理特征的相关性。这项工作纳入了 6 项研究，共 1015 例病例。根据合并数据，较高的 SII 与较差的总生存期 (OS)（HR=2.01，95%CI=1.30-3.09，p=0.002）和 Enneking III 期（OR=2.21，95%CI=1.11）显着相关OSA 患者的 -4.39，p=0.024）。尽管如此，SII与OSA患者的性别、年龄、病理性骨折、肿瘤大小、肿瘤位置、肿瘤分化和转移没有显着相关。综上所述，较高的SII与OSA患者的较差OS和晚期Enneking分期显着相关.https://inplasy.com/inplasy-2024-7-0107/，标识符 IPLASY202470107。版权所有 © 2024 Wang、Wu、Zhang 和 Jiang。

The efficiency of systemic immune-inflammation index (SII) in predicting prognosis of osteosarcoma (OSA) patients has been extensively analyzed, but no consistent findings are obtained. Therefore, this meta-analysis focused on identifying the precise prognostic value of SII for OSA.We comprehensively searched electronic databases of PubMed, Embase, Web of Science, Cochrane Library, and China National Knowledge Infrastructure (CNKI) from inception to 24 February, 2024. Meanwhile, the efficiency of SII in predicting prognosis of OSA was evaluated by calculating pooled hazard ratios (HRs) as well as 95% confidence intervals (CIs). Additionally, the correlation of SII with the OSA clinicopathological characteristics was analyzed based on pooled odds ratios (ORs) and 95%CIs.Six studies with 1015 cases were enrolled into this work. According to the combined data, the higher SII was markedly related to poor overall survival (OS) (HR=2.01, 95%CI=1.30-3.09, p=0.002) and Enneking stage III (OR=2.21, 95%CI=1.11-4.39, p=0.024) of patients with OSA. Nonetheless, SII was not significantly related to gender, age, pathological fracture, tumor size, tumor location, tumor differentiation, and metastasis in patients with OSA.In summary, the higher SII is markedly related to poor OS and advanced Enneking stage in OSA patients.https://inplasy.com/inplasy-2024-7-0107/, identifier INPLASY202470107.Copyright © 2024 Wang, Wu, Zhang and Jiang.